CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 119 enrolled
Drug / intervention
Pregabalin +1 moredrug
Likely dose
Pregabalin 450 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00883740
NCT00883740Phase 3Completed

Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Apr 20, 2009·Updated Jan 25, 2021

In Brief

A Phase 3 clinical trial evaluating Pregabalin and Placebo for Fibromyalgia and Sleep Disorders. Completed, enrolled 119 participants across 50 sites in 3 countries.

Detailed Summary

The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Germany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 20, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.2 years ago

Interventions

Pregabalindrug

Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day

Placebodrug

Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks